Clinical pharmacokinetics of atomoxetine

Clinical Pharmacokinetics

Volumn 44, Issue 6, 2005, Pages 571-590

  Sauer, John Michael ^a   Ring, Barbara J ^b   Witcher, Jennifer W ^b  

^a ELAN PHARMACEUTICALS   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; ATOMOXETINE; DESIPRAMINE; DEXAMPHETAMINE; METHYLPHENIDATE; MIDAZOLAM; PAROXETINE; PEMOLINE; PEMOLINE MAGNESIUM;

AGE DISTRIBUTION; ATTENTION DEFICIT DISORDER; BODY WEIGHT; CLINICAL TRIAL; DEMETHYLATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG INFORMATION; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG SOLUBILITY; FOOD DRUG INTERACTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FUNCTION; LIVER FAILURE; LIVER TOXICITY; MEMBRANE PERMEABILITY; PHYSICAL CHEMISTRY; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RACE DIFFERENCE; REVIEW; SEX DIFFERENCE; STEADY STATE; TOTAL BODY WATER; URINARY EXCRETION;

ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHEMISTRY, PHYSICAL; CHILD; DRUG INTERACTIONS; HUMANS; PROPYLAMINES;

EID: 22244458935     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200544060-00002     Document Type: Review

References (85)

1. Spencer T, Biederman J, Wilens T, et al. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. Child Adol Psychiatry 1996; 35: 409-32
2. Swanson JM, Sergeant JA, Sonuga-Barke EJS, et al. Attention-deficit hyperactivity disorder and hyperkinetic disorder. Lancet 1998; 351: 429-33
3. Weiss G. Follow-up studies on outcome of hyperactive children. Psychopharmacol Bull 1985; 21: 169-77
4. Pary R, Lewis S, Matuschka PR, et al. Attention deficit disorder in adults. Ann Clin Psychiatry 2002; 14: 105-11
5. Adler LA, Chua HC. Management of ADHD in adults. J Clin Psychiatry 2002; 63 Suppl. 12: 29-35
6. Barkley FA, Fischer M, Edelbrock CS, et al. The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1990; 29: 546-57
7. Munir K, Biederman J, Knee D. Psychiatric comorbidity in patients with attention deficit disorder: a controlled study. J Am Acad Child Adolesc Psychiatry 1987; 26: 844-8
8. Biederman J, Newcorn J, Sprich S. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 1991; 148: 564-77
9. Spencer TJ, Biederman J, Wilens TE, et al. Overview and neurobiology of attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002; 63 Suppl. 12: 3-9
10. Volkow ND, Fowler JS, Wang G-J, et al. Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: results from imaging studies. Eur Neuropsychopharmacol 2002; 12: 557-66
11. Giros B, Caron MG. Molecular characterization of the dopamine transporter. Trends Pharmacol Sci 1993; 14: 43-9
12. Patrick KS, Markowitz JS. Pharmacology of methylphenidate, amphetamine enantiomers and pemoline in attention-deficit hyperactivity disorder: a review. Hum Psychopharmacol 1997; 12: 527-46
13. Dackis CA, Gold MS. Addictiveness of central stimulants. Adv Alcohol Subst Abuse 1990; 9: 9-26
14. Markowitz JS, Patrick KS. Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder. Clin Pharmacokinet 2001; 40: 753-72
15. Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings [abstract]. Pediatrics 2001; 107: E105
16. Lyseng-Williamson KA, Keating GM. Extended-release methylphenidate (Ritalin LA). Drugs 2002; 62: 2251-9
17. Tulloch SJ, Zhang Y, McLean A, et al. SLI381 (Adderall XR), a two-component, extended-release formulation of mixed amphetamine salts: bioavailability of three test formulations and comparison of fasted, fed, and sprinkled administration. Pharmacotherapy 2002; 22: 1405-15
18. Wu D, Otton SV, Inaba T, et al. Interactions of amphetamine analogs with human liver CYP2D6. Biochem Pharmacol 1997; 53: 1605-12
19. Nehra A, Mullick R, Ishak KG, et al. Pemoline-associated hepatic injury. Gastroenterology 1990; 99: 1517-9
20. Popper CW. Antidepressants in the treatment of attention-deficit/ hyperactivity disorder. J Clin Psychiatry 1997; 58 Suppl. 14: 14-29
21. Wong DT, Threlkeld PG, Best KL, et al. A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. J Pharmacol Exp Ther 1982; 222: 61-5
22. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002; 27: 699-711
23. Spencer T, Biederman J, Wilens T, et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyper-activity disorder. Am J Psychiatry 1998; 155: 693-5
24. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003; 53: 112-20
25. Michelson D, Faries DE, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with ADHD: a random-ized, placebo-controlled dose-response study [abstract]. Pediatrics 2001; 108: E83
26. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002; 159: 1896-901
27. Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. Am Acad Child Adolesc Psychiatry 2002; 41: 776-84
28. Sauer JM, Ponsler GD, Mattiuz EL, et al. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. Drug Metab Dispos 2003; 31: 98-107
29. Farid NA, Bergstrom RF, Ziege EA, et al. Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects. J Clin Pharmacol 1985; 25: 296-301
30. Belle DJ, Ernest S, Sauer JM, et al. Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J Clin Pharmacol 2002; 42: 1-9
31. Guengerich FP. Human cytochrome P450 enzymes. In: Ortiz de Montellano PR, editor. Cytochrome P450: structure, mechanism, and biochemistry. New York: Plenum Press, 1995: 473-535
32. Sachse C, Brockmoller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60: 284-95
33. Agundez JA, Ledesma MC, Ladero JM, et al. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 1995; 57: 265-9
34. Chalon S, Desager JP, DeSante K, et al. Effect of liver impairment on the pharmacokinetics of atomoxetine and its metabolites. Clin Pharmacol Ther 2003; 73: 178-91
35. Sauer JM, Long AJ, Ring B, et al. Disposition and metabolic fate of atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome. J Pharmacol and Exp Ther 2004; 308: 410-8
36. Witcher JW, Long AJ, Sauer JM, et al. Atomoxetine pharmacokinetics in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2003; 13: 53-64
37. Strattera™ (atomoxetine) package insert (NDA 21-411). Indianapolis (IN); Eli Lilly and Co., 2003
38. Evans DAP, Maghoub A, Sloan TP, et al. A family and population study of the genetic polymorphism of the debrisoquine oxidation in a white British population. J Med Genet 1980; 17: 102-5
39. Steiner E, Bertilsson L, Sawe J, et al. Polymorphic debrisoquine hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther 1988; 44: 431-5
40. DeSante K, Long A, Smith B, et al. Atomoxetine absolute bioavailability and effects of food, Maalox or omeprazole on atomoxetine bioavailability. AAPS Annual Meeting and Exposition; 2001 Oct 21-25; Denver
41. Herman JL, Kou F, Sauer JM, et al. Tissue disposition of 14C-tomoxetine in male Fischer 344 rats following a single oral dose administration. Society for Whole-Body Autoradiography Meeting; 1999 Apr 18-20; St Louis
42. Hamilton MM, Herman JL, Kou F, et al. Placental transfer and milk excretion in rats after a single oral 50 mg/kg dose of [14C]atomoxetine administered as the hydrochloride salt. European Society for Whole Body Autoradiography; 2000, Paris
43. Ring BJ, Gillespie JS, Eckstein JA, et al. Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metab Dispos 2002; 30: 319-23
44. Segel IH. Enzyme kinetics. New York: John Wiley and Sons, Inc., 1975
45. Oberlender R, Nichols DE, Ramachandran PV, et al. Tomoxetine and the stereoselectivity of drug action. J Pharm Pharmcol 1987; 39: 1055-6
46. Gehlert DR, Gackenheimer SL, Robertson DW. Localization of rat brain binding sites for [3H]tomoxetine, an enantiomerically pure ligand for norepinephrine reuptake sites. Neurosci Lett 1993; 157: 203-6
47. Gehlert DR, Schober DA, Gackenheimer SL. Comparison of (R)-[3H]tomoxetine and (R/S)-[3H]nisoxetine binding in rat brain. J Neurochem 1995; 64: 2792-800
48. Heil SH, Holmes HW, Bickel WK, et al. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend 2002; 67: 149-56
49. Wheeler WJ, Bymaster FP, Calligaro DO, et al. Strattera™ (atomoxetine HCl), an inhibitor of the norepinephrine transporter. I: the preparation of C-14 labeled atomoxetine, and two of its metabolites; II: The preparation and biological evaluation of some additional putative metabolites of atomoxetine. In: Dean DC, Filer CN, McCarthy KE, editors. Synthesis and applications of isotopically labelled compounds. Vol 8. New York: John Wiley and Sons, Inc., 2004: 357-60
50. Fuller RW, Hemrick-Luecke SK. Antagonism by tomoxetine of the depletion of norepinephrine and epinephrine in rat brain by alpha-methyl-m-tyrosine. Res Commun Chem Path Pharmacol 1983; 41: 169-72
51. Mattiuz EL, Ponsler GD, Barbuch RJ, et al. Disposition and metabolic fate of atomoxetine hydrochloride: pharmacokinetics, metabolism, and excretion in the fischer 344 rat and beagle dog. Drug Metab Dispos 2003; 31: 88-97
52. Tidey JW, Bergman J. Drug discrimination in metham-phetamine-trained monkeys: agonist and antagonist effects of dopaminergic drugs. J Pharmacol Exp Ther 1998; 285: 1163-74
53. Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry 2002; 63 Suppl. 12: 50-5
54. Wernicke JF, Allen AJ, Faries D, et al. Safety of tomoxetine in clinical trials [abstract]. Biol Psychiatry 2001; 49 (8 Suppl.): 159S
55. Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002; 63: 1140-7
56. Wernicke JF, Faries D, Girod D, et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 2003; 26: 729-40
57. Chouinard G, Annable L, Bradwejn J. An early phase II clinical trial of tomoxetine (LY139603) in the treatment of newly admitted depressed patients. Psychopharmacologia 1984; 83: 126-8
58. Zerbe RL, Rowe H, Enas GG, et al. Clinical pharmacology of tomoxetine, a potential antidepressant. J Pharmacol Exp Ther 1985; 232: 139-43
59. Allen AJ, Wernicke JF, Dunn D, et al. Safety and efficacy of atomoxetine in pediatric CYP2D6 extensive and poor metabolizers. Biol Psychiatry 2001; 49 (8 Suppl.): 37S
60. Caccia S. Metabolism of the newer antidepressants: an overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet 1998; 34: 281-302
61. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997; 32S: 1-21
62. Brøsen K, Hansen JG, Nielsen KK, et al. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 1993; 44: 349-55
63. Özdemir V, Naranjo CA, Herrmann N, et al. Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo. Clin Pharmacol Ther 1997; 62: 334-47
64. Alderman J, Preskorn SH, Greenblatt DJ, et al. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol 1997; 17: 284-91
65. Hemeryck A, Lefebvre RA, De Vriendt C, et al, editor. Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Drug Metab Dispos 2001; 29: 656-63
66. Kobayashi K, Yamamoto T, Chiba K, et al. The effects of selective serotonin reuptake inhibitors and their metablites on S-mephenytoin 4′-hydroxylase activity in human liver microsomes. Br J Clin Pharmacol 1995; 40: 481-5
67. von Moltke LL, Greenblatt DJ, Court MH, et al. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995; 15: 125-31
68. Jeppesen U, Gram LF, Vistisen K, et al. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996; 51: 73-8
69. Martin DE, Zussman BD, Everitt DE, et al. Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men. J Clin Psychopharmacol 1997; 17: 451-9
70. Schmider J, Greenblatt DJ, von Moltke LL, et al. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation. Br J Clin Pharmacol 1997; 44: 495-8
71. Hemeryck A, De Vriendt C, Belpaire FM. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes. Eur J Clin Pharmacol 1999; 54: 947-51
72. Long A, Witcher J, Smith B, et al. Atomoxetine does not alter the plasma pharmacokinetics of desipramine in healthy subjects. AAPS Annual Meeting and Exposition; 2001 Oct 21-25, Denver
73. Spina E, Avenoso A, Campo GM, et al. Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. Br J Clin Pharmacol 1997; 43: 315-8
74. Sanburn N, Long A, Witcher J, et al. Co-administration of atomoxetine hydrochloride and midazolam results in no clinically significant drug-drug interaction. AAPS Annual Meeting and Exposition; 2001 Oct 21-25, Denver
75. Kronbach T, Mathys D, Umeno M, et al. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989; 36: 89-96
76. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994; 55: 481-5
77. Yuan R, Flockhart D, Balian J. Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam. J Clin Pharmacol 1999; 39: 1109-25
78. Witcher JW, Kurtz DL, Sauer JM, et al. Pharmacokinetic/pharmacodynamic relationship of atomoxetine exposure and efficacy in child and adolescent ADHD patients. Philadelphia (PA): American Psychiatric Association, 2002
79. Horai Y, Nakano M, Ishizaki T, et al. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989; 46: 198-207
80. Zanger UM, Eichelbaum M. CYP2D6. In: Levy RH, Thummel KE, Trager WF, et al, editors. Metabolic drug interactions. New York: Lippincott Williams & Wilkins, 2000: 87-94
81. McLellan RA, Oscarson M, Seidegard J, et al. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 1997; 7: 187-91
82. Griese EU, Asante-Poku S, Ofori-Adjei D, et al. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population. Pharmacogenetics 1999; 9: 715-23
83. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002; 3: 229-43
84. Evans W, Relling M, Petros W, et al. Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children. Clin Pharmacol Ther 1989; 45: 568-73
85. Relling M, Cherrie J, Schell M, et al. Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. Clin Pharmacol Ther 1991; 50: 308-13